# Accretion Nutra (NSE: ANL) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ANL · Pivot · prices to 19 Oct 2026

With a market capitalisation of ₹184 Cr, it ranks 2325th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 48.8% in FY25. Promoters held 73.48% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹184 Cr |
| ROE | 48.8% (FY25) |
| ROCE | 51.2% (FY25) |
| Debt to equity | 0.72 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹16 Cr | ₹3 Cr |
| FY24 | ₹5 Cr | ₹1 Cr |
| FY23 | ₹3 Cr | ₹0 Cr |
| FY22 | ₹1 Cr | −₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 73.48%
- Foreign institutions: 1.08%
- Domestic institutions: 6.10%
- Non-institutions: 19.34%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Aashka Hospital](https://app.pivotnow.in/stock/AASHKA) | — | ₹190 Cr | — | — |
| [OXYGENTA PHARMA](https://app.pivotnow.in/stock/OXYGENTAPH) | — | ₹185 Cr | — | — |
| [Earkart](https://app.pivotnow.in/stock/EARKART) | — | ₹182 Cr | — | — |
| [Novelix Pharma](https://app.pivotnow.in/stock/NOVELIX) | — | ₹181 Cr | — | — |
| [Medico Remedies](https://app.pivotnow.in/stock/MEDICO) | ₹21.68 | ₹180 Cr | 13.7 | — |
| [Take Solutions](https://app.pivotnow.in/stock/TAKE) | ₹11.96 | ₹177 Cr | 41.2 | — |

## Questions and answers

### What is the market cap of Accretion Nutra?

Accretion Nutra's market capitalisation is ₹184 Cr (₹184 Cr) at the 19 Oct 2026 close, ranking 2325th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Accretion Nutra?

Return on equity was 48.8% in FY25 and return on capital employed was 51.2% in FY25 (standalone figures).

### Is Accretion Nutra a debt-free company?

No. Accretion Nutra's debt-to-equity ratio was 0.72 in FY25, with total debt of ₹2 Cr.

### What is the shareholding pattern of Accretion Nutra?

As of 30 Jun 2026: promoters 73.48%, foreign institutions 1.08%, domestic institutions 6.10%, non-institutions 19.34%.

### Who are Accretion Nutra's competitors?

The listed Pharma & Healthcare companies closest to Accretion Nutra by market cap are Aashka Hospital, OXYGENTA PHARMA, Earkart, Novelix Pharma, Medico Remedies and Take Solutions.

### Is Accretion Nutra a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Accretion Nutra's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ANL against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.